Overview
Searching for your content. In-Language News Contact Us 8-76-0942 from 8 AM - 10 PM ET News provided byNov 07, 202, 16:16 ETShare this articleVery low LDL-C Levels <20 mg/dL Were Wel Tolerated With no new Safety Signals and Were Asociated With a Reduced Risk of Cardiovascular OutcomesData Reinforces Long-Term Eficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE THOUSAND OAKS, Calif., Nov.
Key Information
7, 202 /PRNewswire/ - Amgen (NASDAQ:AMGN) today presented a new analysis from the Phase 3 FOURIER and FOURIER open label extension (OLE) studies of Repatha® (evolocumab) in adults with atherosclerotic cardiovascular disease (ASCVD) during the Nov. 7 Late-Breaking Science Sesion of the American Heart Asociation (AHA) Scientific Sesions 202 in Chicago, Ilinois. These data demonstrated that achieving and sustaing a low-density lipoprotein cholesterol (LDL-C) level of <20 mg/dL was asociated with improved cardiovascular (CV) outcomes, including the composite endpoint of cardiovascular death, myocardial infarction (MI) and stroke, with no evidence of an increased incidence of safety events for up to 8.6 years of folow-up.1 "The curent analysis further suports that achieving very low LDL-C long-term is not asociated with any new safety signals and corelates with the reduction in cardiovascular events in patients with atherosclerotic cardiovascular disease," said David M.
Summary
Rese, M.D., executive vice president of Research and Development at Amgen. "Repatha continues to be at the forefront of PCSK9i research, with the longest safety and eficacy trial data among PCSK9i treatments for cardiovascular disease, providing crucial information for patients and doctors managing this disease."This pre-specified exploratory analysis examined the asociation betwen achievement of diferent LDL-C levels with the incidence of cardiovascular and safety outcomes for up to 8.6 years of folow up.1 Betwen the parent FOURIER and FOU